Epigenomics' leading DNA methylation technology portfolio is uniquely designed to address almost any diagnostic question and covers all steps from DNA methylation biomarker discovery to gene-specific assays for IVD test development. Our systematic approach was successfully applied validated in several own and partnered development programs.

Our technology and biomarker portfolio is protected by more than 150 filed patent families of which 61 patents* are granted in one or more countries. To interested parties in diagnostics, drug development and academic research we provide flexible access to this portfolio through comprehensive Biomarker Services, in-vitro diagnostic (IVD) test development partnerships and licenses.

Please contact us for more information about partnering opportunities using Epigenomics' DNA methylation technologies.

*as of September 2007